Author: Kyosuke Baba

Our company is currently establishing a groundbreaking collaborative framework with leading domestic research institutions. One example of this is our deepening partnership with the Institute for Quantitative Biosciences at the University of Tokyo (hereafter referred to as IQB). Together with IQB, we are co-developing, implementing, and evolving our proprietary security system, the “IQB Gate”. This …

Read more “Regarding the Development and Implementation of IQB GATE at the University of Tokyo”

Our company has independently developed all the elemental technologies, including our unique completely non-contact and non-invasive biomarker measurement technology. To further advance this technology and improve its accuracy and precision while maintaining our technical and temporal advantages, we have engaged in strategic collaborations with leading domestic research and academic institutions. As one of these initiatives, …

Read more “Commencement of Joint Clinical Research with International Medical Institutions”

A collaborative project utilizing our company’s cutting-edge AI research and development technology has commenced at one of the main campuses of the National University Corporation, The University of Tokyo. Details will be announced once permission is obtained.

Technological Innovation Since our founding in 2015, we have been dedicated to the research and development of our unique technologies, including non-contact and non-invasive biometrics analysis, three-dimensional image analysis, motion detection tracking and matching techniques, and ultra-high-speed application development for edge computing adaptation. We are grateful for the opportunities we’ve had to showcase the results …

Read more “The Pinnacle of Technology and Vision for the Future”

Our non-contact, non-invasive biomarker measurement system, “FLD-A1c®,” has been implemented in an area accessible to researchers, including professors from the University of Tokyo, on one of its major campuses. It is specified that this is part of a collaborative project between our company and the University of Tokyo. We will continue to advance joint projects …

Read more “Our FLD-A1c® system has been implemented at one of the main campuses of the University of Tokyo.”

We has been advancing the development of the FLD® series, which enables contactless and non-invasive measurement of various indicators (biomarkers), including more advanced metrics such as HbA1c, not just oxygen saturation. The development is focused on two main axes: multi-architecture and simultaneous multi-item measurement. Based on this development plan, we have successfully developed the function …

Read more “Development of the iPhone and Android Versions for the FLD® Series HbA1c”

SFM Co., Ltd. has entered into a special agreement with The University of Tokyo (hereinafter referred to as “the University”) with a view towards a new industry-academia collaboration project through joint research. In order to further advance the educational and research environments of the University’s main campuses, we aim to integrate our biomarker measurement technology, …

Read more “Entered into a special agreement with the National University Corporation, the University of Tokyo.”

Our company has successfully registered the trademark for the “FLD-A1c” (this product), the first in the FLD series of non-contact, non-invasive intravascular biomarker analysis devices, with the Patent Office as part of our initiative to strengthen industrial property rights. This registration grants us exclusive commercial rights to the trademark in addition to our prior user …

Read more “Regarding the Completion of Trademark Registration for “FLD-A1c””

The article introduces our “Future Laboratory Data® (FLD®) series,” which enables the non-contact, non-invasive, and highly accurate measurement of biomarkers in the blood.